

## Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

SAN JOSE, Calif., Sept. 27, 2019 /[PRNewswire](#)/ -- **Aridis Pharmaceuticals, Inc.** (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today it will present two posters at the Infectious Disease Society of America's (IDSA) IDWeek™ 2019, taking place October 2-6 in Washington, DC.

### **Poster Presentation Details:**

**Title:** #674 - Pre-Clinical and Phase I Safety Data for Anti-*Pseudomonas aeruginosa* Human Monoclonal Antibody AR-105

**Date:** Thursday, October 3

**Time:** 12:15-1:30pm ET

**Location:** Walter E. Washington Convention Center in Exhibit Hall BC

**Title:** #716 - In Vitro and In Vivo Non Clinical Efficacy of AR-501 (Gallium Citrate)

**Date:** Thursday, October 3

**Time:** 12:15-1:30pm ET

**Location:** Walter E. Washington Convention Center in Exhibit Hall BC

### **About Aridis Pharmaceuticals, Inc.**

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary MablGx® technology platform to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection to produce mAbs. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they do not require genetic engineering or further optimization to achieve full functionality. MablGx® also allows for the selection of any antibody isotype depending on the optimal effector function required for treating the target infection. By bypassing the humanization and binding sequence optimization steps, and the entire process of generation of genetically engineered antibody producing cell lines, MablGx® enables high gross-margins and expedited progression to clinical development.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as VAP and HAP. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The company's pipeline is highlighted below:

### **Aridis' Pipeline**

**AR-301** (VAP). AR-301 is a fully human immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical development targeting gram-positive *S. aureus* alpha-toxin in VAP patients.

**AR-101** (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb targeting *P. aeruginosa* liposaccharides serotype O11, which accounts for approximately 22% of all *P. aeruginosa* hospital acquired pneumonia cases worldwide.

**AR-501** (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 1/2a clinical study in healthy volunteers and CF patients.

**AR-401** (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative *Acinetobacter baumannii*.

**AR-201** (RSV infection). AR-201 is a fully human IgG1 mAb preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).

For additional information on Aridis Pharmaceuticals, please visit <https://aridispharma.com/>.

### **Contact:**

Investor Relations

Jason Wong

Blueprint Life Science Group  
[jwong@bplifescience.com](mailto:jwong@bplifescience.com)  
(415) 375-3340 Ext. 4

SOURCE Aridis Pharmaceuticals, Inc.

---

<https://investors.aridispharma.com/2019-09-27-Aridis-Pharmaceuticals-to-Present-AR-105-and-AR-501-Gallium-Citrate-Data-at-IDWeek-TM-2019>